Emma Hardy

The hon. Gentleman raises an important point. We would of course look at whatever powers we have at our disposal, but as a Government we do not want to see costs unfairly increased for Northern Ireland customers. That is the important principle that we are trying to address by doing this. We hope that that will not be the case, but if it is, we would need to work closely and carefully with all stakeholders in Northern Ireland, and we would of course follow up with meetings with representatives from Northern Ireland about that. We are not complacent. The Government’s position is based on our assessment of the best possible evidence available, and we take stakeholder concern extremely seriously. As I mentioned at the beginning, Baroness Hayman was in Northern Ireland just last week for a couple of days, meeting with people about this very issue. I know that it is something she cares about and sees as incredibly important. Our view is based on what we can see. The transition to new arrangements at the end of the year will be manageable, but if there are unexpected problems, we have our two schemes to manage that. I also note that there will not be a cliff edge on supply at the end of the year. All medicines supplied to Northern Ireland before the end of this year will remain available, and some of those products have long shelf lives. We have advised businesses to take prudent action, but that is just in case. We have put in many different mitigations to try and resolve this issue. We will continue to monitor the situation closely, and we will respond rapidly if issues arise. As I mentioned at the beginning of my speech, we want to continue and maintain open dialogue with all representatives.